Critical roles of mucin-1 in sensitivity of lung cancer cells to tumor necrosis factor-alpha and dexamethasone

Xu, Menglin; Wang, Xiangdong

doi:10.1007/s10565-017-9393-x

Cited by 25 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MUC1 is a transmembrane glycoprotein that is aberrantly glycosylated in many cancers, including NSCLC. 253,254 MUC1 and PSCA CAR-T cells showed independent and synergistic antitumor efficacy in a patient-derived xenograft model of NSCLC. 255 The First People's Hospital in Hefei, China is completing a Phase I/ II study of MUC1-CAR T cells for patients with MUC1+ advanced refractory NSCLC (NCT02587689).…”

Section: Ctla-4 Antibodymentioning

confidence: 95%

Making cold malignant pleural effusions hot: driving novel immunotherapies

et al. 2019

View full text Add to dashboard Cite

Malignant pleural effusions, arising from either primary mesotheliomas or secondary malignancies, heralds advanced disease and poor prognosis. Current treatments, including therapeutic thoracentesis and tube thoracostomy, are largely palliative. The immunosuppressive environment within the pleural cavity includes myeloid derived suppressor cells, T-regulatory cells, and dysfunctional T cells. The advent of effective immunotherapy with checkpoint inhibitors and adoptive cell therapies for lung cancer and other malignancies suggests a renewed examination of local and systemic therapies for this malady. Prior strategies reporting remarkable success, including instillation of the cytokine interleukin-2, perhaps coupled with checkpoint inhibitors, should be further evaluated in the modern era.

show abstract

Section: Ctla-4 Antibodymentioning

confidence: 95%

Making cold malignant pleural effusions hot: driving novel immunotherapies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Furthermore, MUC1 serves critical roles in the regulation of the phosphoinositide 3-kinase/protein kinase B (AKT) and B-cell lymphoma-xL pathway activation. A previous study (11) suggested that MUC1 may be a novel target for lung cancer treatment, and may be involved in the regulation of lung cancer cell growth. However, the exact role of MUC1 in NSCLC progression and the underlying molecular mechanisms involved remain poorly understood.…”

Section: Introductionmentioning

confidence: 99%

MUC1 downregulation inhibits non‑small cell lung cancer progression in human cell lines

Wang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. Mucin 1 (MUC1) is a transmembrane glycoprotein that is aberrantly unregulated in numerous types of cancer, including non-small cell lung cancer (NSCLC), and serves a key role as an oncogene in the tumorigenesis of various human adenocarcinomas. Studies have indicated that MUC1 is involved in cell proliferation, invasion and migration. However, the role of MUC1 in NSCLC progression remains poorly understood. The aim of the present study was to investigate the role of MUC1 in stable MUC1-low-expression NSCLC cell lines that were generated by transfection with MUC1-siRNA. Cell Counting Kit-8 assay was preformed to determine the proliferation ability of NSCLC cells, while cell apoptosis was detected using flow cytometry. In addition, the mRNA and protein expression levels of MUC1 were detected by reverse transcription-quantitative polymerase chain reaction and western blot analysis, respectively. Western blot analysis was also used for detection of other associated proteins. The results demonstrated that, compared with the control group, the cell proliferation ability was significantly declined in the MUC1 inhibition group, and the cell apoptosis rate was markedly increased. Inhibition of MUC1 gene in NCI-H1650 cells suppressed cell proliferation and induced cell apoptosis. In addition, the protein expression levels of vascular endothelial growth factor (VEGF) and VEGF-C were notably decreased by MUC1 inhibition, indicating the anti-angiogenic effect of MUC1 downregulation. Furthermore, inhibition of MUC1 gene with MUC1-siRNA significantly suppressed the phosphorylation of protein kinase B and extracellular signal-regulated kinase. In conclusion, the findings indicated that silencing of MUC1 gene may inhibit the development of NSCLC cells.

show abstract

“…Clinical lipidomics plays the important role in prevention, diagnosis, and potential therapies, through the understanding of links between the lipids and their corresponding diseases. The identification and development of disease-specific biomarkers using clinical lipidomics require defining lipidomic profiles correlated with disease types and subtypes, severities, durations, and phases, especially with clinical phenomes (Wang X. Wang 2018 ; Wang X. Wang 2016 ; Xu M et al Xu and Wang 2017 ; Zhu Z. Zhu et al 2017 ). The discovery of lipid-based biomarkers can be an alternative for the diagnosis of various diseases, such as phosphatidylinositol (PI) species, PI (16:0–16:1) and PI (18:0–20:4) as potential biomarkers for breast cancer (Postle AD.…”

mentioning

confidence: 99%

Is the clinical lipidomics a potential goldmine?

Zhang

Han²,

Wang

2018

Cell Biol Toxicol

Self Cite

View full text Add to dashboard Cite

Clinical lipidomics is a new extension of lipidomics to study lipid profiles, pathways, and networks by characterizing and quantifying the complete lipid molecules in cells, biopsy, or body fluids of patients. It undoubtfully has more values if lipidomics can be integrated with the data of clinical proteomic, genomic, and phenomic profiles. A number of challenges, e.g., instability, specificity, and sensitivity, in lipidomics have to be faced and overcome before clinical application. The association of lipidomics data with gene expression and sequencing of lipid-specific proteins/enzymes should be furthermore clarified. Therefore, clinical lipidomics is expected to be more stable during handling, sensitive in response to changes, specific for diseases, efficient in data analyses, and standardized in measurements, in order to meet clinical needs. Clinical lipidomics will become a more important approach in clinical applications and will be the part of “natural” measures for early diagnosis and progress of disease. Thus, clinical lipidomics will be one of the most powerful approaches for disease-specific diagnosis and therapy, once the mystery of lipidomic profiles and metabolic enzymes is deciphered.

show abstract

Critical roles of mucin-1 in sensitivity of lung cancer cells to tumor necrosis factor-alpha and dexamethasone

Cited by 25 publications

References 29 publications

Making cold malignant pleural effusions hot: driving novel immunotherapies

Making cold malignant pleural effusions hot: driving novel immunotherapies

MUC1 downregulation inhibits non‑small cell lung cancer progression in human cell lines

Is the clinical lipidomics a potential goldmine?

Contact Info

Product

Resources

About